First AD

Second AD

Tony Hagen is senior managing editor for The Center for Biosimilars

Episode 1. California’s “Pay-for-Delay” Law

Episode 2. The FDA Reaches Out to the US Patent and Trademark Office

Episode 3. The Build Back Better Act and Biosimilars

Episode 4. Defining Interchangeable Biosimilars More Clearly

News

Business

Development

Regulatory

Policy

The Center for Biosimilars® spoke recently with Chad Landmon, chair of the Intellectual Property and Food and Drug Administration Practice Groups at Axinn, a New York–based antitrust, intellectual property, and litigation law firm.

Biosimilar Legal and Business Developments in 2021